People who use drugs show no increase in pre-existing T-cell cross-reactivity toward SARS-CoV-2 but develop a normal polyfunctional T-cell response after standard mRNA vaccination.

Autor:	Gainullin M; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; NEC OncoImmunity AS, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Federico L; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Røkke Osen J; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Chaban V; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Kared H; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Alirezaylavasani A; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway., Lund-Johansen F; Department of Immunology, Oslo University Hospital, Oslo, Norway.; ImmunoLingo Convergence Center, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Wildendahl G; Agency for Social and Welfare Services, Oslo, Norway., Jacobsen JA; Agency for Social and Welfare Services, Oslo, Norway., Sarwar Anjum H; Agency for Social and Welfare Services, Oslo, Norway., Stratford R; NEC OncoImmunity AS, Oslo, Norway., Tennøe S; NEC OncoImmunity AS, Oslo, Norway., Malone B; NEC OncoImmunity AS, Oslo, Norway., Clancy T; NEC OncoImmunity AS, Oslo, Norway., Vaage JT; Department of Immunology, Oslo University Hospital, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Henriksen K; Agency for Social and Welfare Services, Oslo, Norway.; Student Health Services, University of Oslo, Oslo, Norway., Wüsthoff L; Unit for Clinical Research on Addictions, Oslo University Hospital, Oslo, Norway.; Norwegian Centre for Addiction Reasearch, Institute of Clinical Medicine, University of Oslo, Oslo, Norway., Munthe LA; KG Jebsen Centre for B cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Immunology, Oslo University Hospital, Oslo, Norway.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2024 Jan 17; Vol. 14, pp. 1235210. Date of Electronic Publication: 2024 Jan 17 (Print Publication: 2023).
DOI:	10.3389/fimmu.2023.1235210
Abstrakt:	People who use drugs (PWUD) are at a high risk of contracting and developing severe coronavirus disease 2019 (COVID-19) and other infectious diseases due to their lifestyle, comorbidities, and the detrimental effects of opioids on cellular immunity. However, there is limited research on vaccine responses in PWUD, particularly regarding the role that T cells play in the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we show that before vaccination, PWUD did not exhibit an increased frequency of preexisting cross-reactive T cells to SARS-CoV-2 and that, despite the inhibitory effects that opioids have on T-cell immunity, standard vaccination can elicit robust polyfunctional CD4 + and CD8 + T-cell responses that were similar to those found in controls. Our findings indicate that vaccination stimulates an effective immune response in PWUD and highlight targeted vaccination as an essential public health instrument for the control of COVID-19 and other infectious diseases in this group of high-risk patients. Competing Interests: Authors MG, RS, ST, BM and TC were employed by company NEC OncoImmunity AS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Gainullin, Federico, Røkke Osen, Chaban, Kared, Alirezaylavasani, Lund-Johansen, Wildendahl, Jacobsen, Sarwar Anjum, Stratford, Tennøe, Malone, Clancy, Vaage, Henriksen, Wüsthoff and Munthe.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu